Celcuity (CELC) vs Tarsus Pharmaceuticals (TARS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Celcuity (CELC) has outperformed Tarsus Pharmaceuticals (TARS) over the past year, gaining 33.4% versus a gain of 7.2%. Over five years, CELC leads with a +260.8% price change compared with +157.3% for TARS. Tarsus Pharmaceuticals is the larger company by market cap ($3.44 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | TARS |
|---|---|---|
| Share price | $65.78 | $73.61 |
| Market cap | $3.22B | $3.44B |
| 1-day change | -7.68% | -0.67% |
| YTD return | -34.16% | -10.39% |
| 1-year return | +33.43% | +7.23% |
| 5-year return | +260.82% | +157.26% |
| EPS (TTM) | $-4.17 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $91.53 |
| 52-week low | $45.03 | $53.89 |
| Distance from 52-week high | -56.44% | -19.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +35.17% |
| Average volume | 1.19M | 906.66K |
| Shares outstanding | 48.93M | 46.79M |
| Employees | 155 | 370 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELC has outperformed TARS by 26.2 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Healthcare · Biotechnology · 155 employees
About Tarsus Pharmaceuticals
TARS stock →Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Healthcare · Biotechnology · 370 employees
CELC vs TARS FAQ
Which is bigger, Celcuity or Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals (TARS) is larger, with a market capitalization of $3.44B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or TARS?
CELC returned +33.43% over the past 12 months, compared with +7.23% for TARS (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Tarsus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.